Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA (GOLMEPsA) (GOLMePsA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04108468
Recruitment Status : Recruiting
First Posted : September 30, 2019
Last Update Posted : September 30, 2019
Janssen Pharmaceutica N.V., Belgium
Information provided by (Responsible Party):
The Leeds Teaching Hospitals NHS Trust

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : September 2021